Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis

Arthritis and Rheumatism

Volumn 64, Issue 1, 2012, Pages 232-242

  Tsai, Pei Yi ^a   Ka, Shuk Man ^a   Chang, Jia Ming ^a   Lai, Jenn Haung ^a   Dai, Ming Shen ^a   Jheng, Huei Lin ^a   Kuo, Mao Tien ^b   Chen, Peini ^b   Chen, Ann ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Golden Biotechnology   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTROQUINONOL; FUNGAL EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ACCELERATED SEVERE LUPUS NEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTRODIA CAMPHORATA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLOMERULUS; HEMATURIA; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUGS, CHINESE HERBAL; IMMUNOGLOBULIN G; INTERLEUKIN-18; KIDNEY; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NZB; NF-E2-RELATED FACTOR 2; PLANT EXTRACTS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; UBIQUINONE;

EID: 84855288749     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33328     Document Type: Article

References (50)

1. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50. (Pubitemid 38140764)
2. Tam LS, Li EK, Lai FM, Chan YK, Szeto CC,. Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus 2003; 12: 665-71. (Pubitemid 37173662)
3. Mittal B, Hurwitz S, Rennke H, Singh AK,. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004; 44: 1050-9. (Pubitemid 39556485)
4. Casciola-Rosen LA, Anhalt G, Rosen A,. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30. (Pubitemid 24091790)
5. Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007; 28: 114-21. (Pubitemid 46680499)
6. Tucci M, Stucci S, Strippoli S, Silvestris F,. Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 457146.
7. Shui HA, Ka SM, Wu WM, Lin YF, Hou YC, Su LC, et al. LPS-evoked IL-18 expression in mesangial cells plays a role in accelerating lupus nephritis. Rheumatology (Oxford) 2007; 46: 1277-84.
8. Haas KM, Watanabe R, Matsushita T, Nakashima H, Ishiura N, Okochi H, et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 2010; 184: 4789-800.
9. Su W, Madaio MP,. Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells. Semin Nephrol 2003; 23: 564-8. (Pubitemid 38030090)
10. Bagavant H, Fu SM,. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009; 21: 489-94.
11. Fenton K, Fismen S, Hedberg A, Seredkina N, Fenton C, Mortensen ES, et al. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One 2009; 4: e8474.
12. Zykova SN, Tveita AA, Rekvig OP,. Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis. PLoS One 2010; 5: e12096.
13. Summers SA, Steinmetz OM, Li M, Kausman JY, Semple T, Edgtton KL, et al. Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 2009; 20: 2518-24.
14. Morimoto S, Tokano Y, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, et al. Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis. Autoimmunity 2009; 42: 143-9.
15. Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F,. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 2005; 4: 542-8. (Pubitemid 41415767)
16. Tucci M, Ciavarella S, Strippoli S, Dammacco F, Silvestris F,. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells: a review. Ann N Y Acad Sci 2009; 1173: 449-57.
17. Moradi H, Pahl MV, Elahimehr R, Vaziri ND,. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85.
18. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF,. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62: 2064-72.
19. Tang S, Lui SL, Lai KN,. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton) 2005; 10: 174-9. (Pubitemid 40776278)
20. Kim HJ, Vaziri ND,. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-71.
21. Modlinger PS, Wilcox CS, Aslam S,. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24: 354-65. (Pubitemid 38900635)
22. Nguyen T, Nioi P, Pickett CB,. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-5.
23. Kaspar JW, Niture SK, Jaiswal AK,. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009; 47: 1304-9.
24. Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001; 60: 1343-53. (Pubitemid 32960028)
25. Molino C, Fabbian F, Longhini C,. Clinical approach to lupus nephritis: recent advances. Eur J Intern Med 2009; 20: 447-53.
26. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, et al. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 2009; 48: 176-82.
27. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC,. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
28. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57. (Pubitemid 32799338)
29. Lee TH, Lee CK, Tsou WL, Liu SY, Kuo MT, Wen WC,. A new cytotoxic agent from solid-state fermented mycelium of Antrodia camphorata. Planta Med 2007; 73: 1412-5.
30. Hseu YC, Huang HC, Hsiang CY,. Antrodia camphorata suppresses lipopolysaccharide-induced nuclear factor-κB activation in transgenic mice evaluated by bioluminescence imaging. Food Chem Toxicol 2010; 48: 2319-25.
31. Chang JM, Lee YR, Hung LM, Liu SY, Kuo MT, Wen WC, et al. An extract of Antrodia camphorata mycelia attenuates the progression of nephritis in systemic lupus erythematosus-prone NZB/W F1 mice. Evid Based Complement Alternat Med 2008. E-pub ahead of print.
32. Hseu YC, Chang WC, Hseu YT, Lee CY, Yech YJ, Chen PC, et al. Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci 2002; 71: 469-82.
33. Yang HL, Chen CS, Chang WH, Lu FJ, Lai YC, Chen CC, et al. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata. Cancer Lett 2006; 231: 215-27.
34. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, et al. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 2010; 79: 162-71.
35. Cavallo T, Granholm NA,. Accelerated (proliferative) lupus nephritis. Am J Pathol 1990; 137: 1549-51.
36. Cavallo T, Granholm NA,. Bacterial lipopolysaccharide transforms mesangial into proliferative lupus nephritis without interfering with processing of pathogenic immune complexes in NZB/W mice. Am J Pathol 1990; 137: 971-8. (Pubitemid 20337811)
37. Granholm NA, Cavallo T,. Enhancement of renal disease in BXSB lupus prone mice after prior exposure to bacterial lipopolysaccharide. Lupus 1995; 4: 339-47.
38. Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A,. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol 2007; 18: 2473-85. (Pubitemid 47378864)
39. Tsai PY, Ka SM, Chao TK, Chang JM, Lin SH, Li CY, et al. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 2011; 50: 1503-16.
40. Schwartz MM, Korbet SM, Lewis EJ,. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008; 23: 1298-306. (Pubitemid 351767497)
41. Hill GS, Delahousse M, Nochy D, Bariety J,. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68: 2288-97. (Pubitemid 43117806)
42. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-88. (Pubitemid 46233461)
43. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY,. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005; 22: 329-41. (Pubitemid 40387475)
44. Dong G, Ye R, Shi W, Liu S, Wang T, Yang X, et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 2003; 116: 543-8. (Pubitemid 36675854)
45. Agarwal S, Misra R, Aggarwal A,. Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. Rheumatol Int 2009; 29: 907-11.
46. Akhtar S, Li X, Kovacs EJ, Gamelli RL, Choudhry MA,. Interleukin-18 delays neutrophil apoptosis following alcohol intoxication and burn injury. Mol Med 2011; 17: 88-94.
47. Costantini C, Micheletti A, Calzetti F, Perbellini O, Pizzolo G, Cassatella MA,. Neutrophil activation and survival are modulated by interaction with NK cells. Int Immunol 2010; 22: 827-38.
48. Silliman CC, Kelher MR, Gamboni-Robertson F, Hamiel C, England KM, Dinarello CA, et al. Tumor necrosis factor-α causes release of cytosolic interleukin-18 from human neutrophils. Am J Physiol Cell Physiol 2010; 298: C714-24.
49. Lenda DM, Stanley ER, Kelley VR,. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J Immunol 2004; 173: 4744-54. (Pubitemid 39280711)
50. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N,. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 1995; 5: 1483-91.